Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Shanghai YingLi Pharmaceutical Co. Ltd.)"
Count: 16
Selected: 0
NCT IDTitle
NCT05228600YL-13027 in Patients With Advanced Solid Tumors
NCT05119933A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
NCT05457517A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors
NCT05429398A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor
NCT05274997A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
NCT05173805A Phase 1, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
NCT04975061A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer
NCT04705090A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
NCT04500561YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial
NCT04379167A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma
NCT04370405A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma
NCT04279405A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
NCT04108325A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT04049929A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors
NCT03869632First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors
NCT03757000A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies